Aptevo Therapeutics Inc.
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -9.02% | -63.83% | -74.84% | -79.97% | -78.43% |
| Gross Profit | 9.02% | 63.83% | 74.84% | 79.97% | 73.88% |
| SG&A Expenses | -13.14% | -12.29% | -12.22% | -16.09% | -15.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.81% | -18.47% | -17.36% | -8.71% | -9.06% |
| Operating Income | 14.81% | 18.47% | 17.36% | 8.71% | -0.83% |
| Income Before Tax | -29.38% | -36.30% | -32.23% | -263.39% | -365.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.38% | -36.30% | -32.23% | -263.39% | -365.91% |
| Earnings from Discontinued Operations | -- | -80.03% | -82.05% | -83.55% | 22.31% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.58% | -46.87% | -42.91% | -246.07% | -316.92% |
| EBIT | 14.81% | 18.47% | 17.36% | 8.71% | -0.83% |
| EBITDA | 14.35% | 18.13% | 16.86% | 7.81% | -2.06% |
| EPS Basic | -3.93% | -- | -- | -- | -- |
| Normalized Basic EPS | 0.98% | -- | -- | -- | -- |
| EPS Diluted | -3.92% | -- | -- | -- | -- |
| Normalized Diluted EPS | 0.98% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 8,900.74% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 8,900.74% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |